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Abstract
Background: Viruses interact with and exploit the host cellular machinery for their multiplication and propagation. The
MEK/ERK signaling pathway positively regulates replication of many RNA viruses. However, whether and how this signaling
pathway affects hepatitis C virus (HCV) replication and production is not well understood.
Methods and Results: In this study, we took advantage of two well-characterized MEK/ERK inhibitors and MEK/ERK
dominant negative mutants and investigated the roles of the MEK/ERK signaling pathway in HCV gene expression and
replication. We showed that inhibition of MEK/ERK signaling enhanced HCV gene expression, plus- and minus-strand RNA
synthesis, and virus production. In addition, we showed that this enhancement was independent of interferon-a (IFN-a)
antiviral activity and did not require prior activation of the MEK/ERK signaling pathway. Furthermore, we showed that only
MEK and ERK-2 but not ERK-1 was involved in HCV replication, likely through regulation of HCV RNA translation.
Conclusions: Taken together, these results demonstrate a negative regulatory role of the MEK/ERK signaling pathway in
HCV replication and suggest a potential risk in targeting this signaling pathway to treat and prevent neoplastic
transformation of HCV-infected liver cells.
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Introduction
Hepatitis C virus (HCV) causes chronic hepatitis, cirrhosis, and
hepatocellular carcinoma (HCC) [1]. There are approximately
170 million infected people worldwide [2] and no therapeutic or
prophylactic vaccines currently available. Therefore, HCV
continues to represent a significant public health problem that
mandates intensified efforts and investment in both clinical
management and research.
HCV belongs to the hepacivirus genus in the flaviviridae family. It
is a plus-strand RNA virus with a genome of approximate 9.6 kb.
It contains a single open reading frame (ORF) encoding a single
polyprotein precursor of 3,010 amino acids. The ORF is flanked
by 59 and 39 untranslated regions (UTR). Viral proteins are
translated through an internal ribosome entry site (IRES)-
dependent mechanism. The precursor polyprotein is processed
co- and post-translationally by cellular and viral proteases into 10
proteins: structural proteins (core, E1, and E2), a small membrane-
associated protein p7, and six nonstructural (NS) proteins NS2, 3,
4A, 4B, 5A, and 5B [3].
The outcomes of HCV infection vary among individuals. Only
a few percentage of the infected individuals are able to clear and
resolve the infection, the remaining majority (50–80%) develop
chronic hepatitis and other liver complications [2]. The viral
mechanisms of chronic infection and the cellular determinants of
infection clearance are poorly understood. Many viruses including
HCV have developed sophisticated mechanisms to evade or
antagonize cellular anti-viral responses, leading to persistent and/
or chronic infection. The Raf/MEK/ERK signaling pathway is
one of the mitogen-activated protein kinase (MAPK) cascades and
plays important roles in the regulation of cell growth, differenti-
ation, survival, and transmission of oncogenic signals [4]. This
pathway is activated by a variety of stimuli including growth
factors, mitogens, transforming agents, and virus infections. Upon
stimulation, activated Raf kinase activates MEK1/2, which in turn
activates ERK1/2 to phosphorylate substrates in the cytoplasm or
to translocate to the nucleus to phosphorylate transcription factors
and regulate target gene expression. MAPK also phosphorylates
and activates other kinases termed MAPK-activated protein
kinases including the 90-kDa ribosomal S6 kinases, the mitogen-
and stress-activated kinases, and the MAPK-interacting kinases
[5].
Viruses are intracellular obligate parasites; they have evolved to
exploit the host cellular machinery for their replication. The
MEK/ERK signaling pathway plays an important role in their
replication. Activation of the MEK/ERK signaling cascade
enhances replication of viruses such as human immunodeficiency
virus [6], influenza virus [7], borna disease virus [8], coronavirus
[9], coxsakievirus B3 [10], and herpes simples virus [11]. The
underlying molecular mechanisms include interference with viral
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defense. On the other hand, activation of the MEK/ERK
signaling leads to inhibitory effects of virus replication as in the
case of hepatitis B virus, a hepatotropic virus which like HCV
induces hepatocellular carcinoma in infected hosts [12]. Mean-
while, interleukin-1 (IL-1) inhibits HCV replication in HCV
subgenomic replicon cells through activation of ERK and
induction of interferon (IFN)-stimulated gene 1-8U; MEK
inhibitor PD98059 abrogates the inhibitory effects of IL-1 on
HCV replication [13]. IL-1 is also involved in IFN-a-mediated
antiviral gene induction in human hepatoma cells [14]. Taken
together, these findings indicate that IL-1-mediated ERK
activation induces an anti-viral effect. As the nature of the stimuli
determines the final outcome of the signaling, it is conceivable that
other stimuli of ERK signaling may have different effects on HCV
replication. Moreover, it is not known whether and how the
MEK/ERK signaling affects HCV replication. Therefore, in this
study we aimed to characterize the role of this signaling pathway
in HCV replication and production using both HCV subgenomic
replicon and full-length genomic systems.
Materials and Methods
Cell culture and reagents
Huh 7-based HCV subgenomic replicon cells carrying a Renilla
luciferase (RLuc) reporter were described elsewhere [15] and
maintained in DMEM supplemented with 10% FBS, 1%
penicillin/streptomycin/L-glutamine, 1X non-essential amino-
acids, and 250 mg/ml G418. Huh 7 cells were a gift from Dr.
Steve Polyak of University of Washington, Seattle; Huh 7.5 cells
were obtained from Dr. Charles Rice of Rockefeller University,
New York. Both cells were maintained as Huh 7 HCV replicon
cells except for that no G418 was present in the culture medium.
ERK-1 mAb was from BD Biosciences (San Jose, CA), MEK1/2
mAb from Cell Signaling Technology (Danvers, MA), HCV core
mAb from Affinity Bioreagents (Golden, CO), HA antibody from
Santa Cruz Biotechnologies (Santa Cruz, CA), and b-actin mAb
from Sigma (Saint Louis, MO). MEK inhibitors U0126 and
PD98059 were from Cell Signaling Technology and were
reconstituted in DMSO. Interferon-a/2b (IFN-a/2b) was pur-
chased from PBL Biomedical Laboratories (Piscataway, NJ) and
reconstituted in PBS.
Plasmids
pCR2.1-b-actin was constructed by PCR-cloning of b-actin
fragment into pCR2.1-TOPO vector (Invitrogen, Carlsbad, CA).
pFL-JFH1 was obtained from Dr. Takaji Wakita [16]. Dominant
negative MEK-1, ERK-1, and ERK-2 were described elsewhere
[17]. pGEM-3Z-59UTR was previously constructed [18].
pC3.RLuc.HCV IRES.FLuc was constructed from pC3.RLuc.-
Polio IRES.Fluc, a gift from Dr. Nahum Sonenberg of McGill
University, Canada by replacing the polio IRES fragment with the
HCV IRES at Kpn I and BamH I restriction sites.
In vitro RNA transcription
HCV RLuc replicon construct was linearized with Sca I,
purified, and transcribed with MEGAscript
TM T7 RNA tran-
scription kit (Ambion, Austin, TX). The RNA transcripts were
treated with 2 U DNase I at 37uC for 30 min, purified by acid
phenol chloroform extraction, and suspended in diethylpyrocar-
bonate-treated water. To synthesize the full-length HCV JFH-1
RNA, the pFL-JFH1 plasmid was linearized with Xba I, purified,
and used as template for in vitro transcription as above.
Transcribed RNA was stored in aliquots at 280uC.
Transfection of HCV RNA, plasmids, and siRNA
Cells were plated in a 24-well plate at a density of 8610
4 cells
per well or in a 6-well plate at a density of 8610
5 cells per well.
Transfection of HCV RNA and dominant negative constructs
were performed using Lipofectamine 2000 reagents (Invitrogen)
according to the manufacturer’s instructions. ERK-1-specific
siRNA and control siRNA were purchased from Ambion and
transfected into the cells using Oligofectamine (Invitrogen)
following the manufacturer’s instructions. In all transfections, the
cells were washed by and replaced with the fresh medium 24 hr
after transfection.
Immunoblotting
Cell lysates were prepared at 48 hr post transfection with a
standard RIPA buffer and separated on a 12% polyacrylamide-
SDS gel. The proteins were transferred onto the nitrocellulose
membrane, probed with appropriate primary antibodies and
HRP-conjugated secondary antibodies, and were visualized by the
enhanced chemiluminescence (VWR, West Chester, PA). As
indicated, membrane was stripped and re-probed with anti-b-actin
mAb.
Luciferase reporter gene assay
HCV RLuc replicon cells were grown in a 24-well plate and
treated with MEK inhibitors or their solvent DMSO for 24 hr or
pre-treated with IFN-a/2b or its solvent PBS prior to treatment
with MEK inhibitors or DMSO. The luciferase assay was
performed using a Renilla luciferase assay kit (Promega, Madison,
WI) according to the manufacturer’s instructions. In experiments
involving dominant negative constructs and siRNA, HCV RLuc
replicon cells were transfected with these plasmids or siRNA,
cultured for 48 hr, and then harvested for the luciferase assay. All
luciferase assays were done in triplicates and the results were
expressed as mean6SEM. The difference was considered
statistically significant when the p value was less than 0.05.
RNase protection assay (RPA)
HCV RLuc replicon cells were grown in a 6-well plate, treated
with MEK inhibitors and/or IFN-a/2b or transfected with
siRNAs as indicated. Total RNA was isolated using TRIzolHRea-
gent (Invitrogen). b-actin probe and HCV sense and anti-sense
59UTR probes were synthesized using pCR2.1-b-actin and
pGEM-3Z-59UTR as respective templates and a Maxiscript
TM
RNA transcription kit (Ambion) according to the manufacturer’s
instructions. The RPA was performed with a BD RiboQuant
TM
ribonuclease protection assay kit (BD Biosciences) as described
elsewhere [18]. Briefly, 10 mg total RNA was hybridized with
80,000 cpm [a-
32P] UTP-labeled 59UTR anti-sense or sense
probe for detection of plus- or minus-strand HCV RNA
respectively. The b-actin RNA was used as an internal equal
RNA loading control and detected with 5,000 cpm [a-
32P] UTP-
labeled b-actin anti-sense probe. The protected probes were
analyzed on 6% polyacrylamide-7.5 M urea gel and visualized by
autoradiography.
Quantitative real-time RT-PCR for HCV RNA
The culture supernatant from Huh 7.5 cells transfected with
HCV JFH-1 RNA was collected, filtered through 0.22 mm filter,
and concentrated by about 30 times using an AmiconH Ultra-15
Centrifugal Filter Unit (MW cut-off 100 kDa) (Millipore, Bedford,
MA). The RNA was isolated from the concentrated supernatant
using a QIAampH Viral RNA Mini Kit (Qiagen, Valencia, CA) to
determine HCV production in the cell culture supernatant.
MEK/ERK and HCV Replication
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cells. Both RNA were quantitated in triplicates using a TaqManH
OneStep RT-PCR Master Mix Reagents Kit (Applied Biosystems,
Foster City, CA) and the primers and probes described previously
[19]. The reactions were performed on a Mx3000P QPCR system
(Stratagene, La Jolla, CA) with a program of 48uC for 30 min,
95uC for 10 min, and then 50 cycles at 95uC for 15 sec and 60uC
for 1 min. The absolute HCV RNA level was calculated using in
vitro transcribed JFH-1 RNA standards.
Results
MEK inhibitors enhanced HCV replication
To determine the relationship between MEK/ERK signaling
and HCV replication, we took advantage of two well-character-
ized and widely used MEK inhibitors (U0126 and PD98059).
U0126 inhibits the active and inactive forms of MEK1/2, while
PD98059 inhibits the activation of inactive MEK1/2 [20,21]. In
the preliminary experiments, we titrated the concentrations of
U0126 and PD98059 for a maximal MEK/ERK inhibitory effect
while with little cytotoxicity and confirmed the optimal concen-
trations for U0126 and PD98059 to be 5 mM and 10 mM,
respectively for their combined use (data not shown). We then used
these concentrations to examine the effects of these inhibitors on
HCV replication in HCV RLuc replicon cells. Compared to the
DMSO control, treatment of MEK inhibitors resulted in a
significant increase in the luciferase reporter gene activity (Fig. 1A).
We next determined whether these inhibitors affected HCV RNA
synthesis. To distinguish between plus- and minus-strand HCV
RNA syntheses, we performed the RNase protection assay using
the strand-specific probes. Before using this assay, we tested the
strand specificity on in vitro transcribed HCV 59 UTR RNA of
plus- and minus-polarities by hybridization with the anti-sense and
sense probes, we found that the sense probe only detected the
minus-strand RNA and the anti-sense probe only detected the
plus-strand RNA and that there was no cross by hybridization
(data not shown). Treatment of the inhibitors increased plus-strand
HCV RNA level by about 3.5 fold over the DMSO control
(Fig. 1B) and had only a slight increase of minus-strand HCV
RNA level over the DMSO control (Fig. 1C). Taken together,
these results provide the first evidence that inhibition of the MEK/
ERK signaling enhanced HCV gene expression and replication.
Enhancement of HCV replication by MEK inhibitors was
independent of IFN-a anti-viral activity
HCV replication is inhibited by IFN-a treatment [22]. IFN-a
binds to its cognate receptors and activates the JAK/STAT
s i g n a l i n g ,w h i c hi nt u r ni n d u c e se f f e c t o r ss u c ha sM x Ag u a n o s i n e
triphosphatase, dsRNA activated-protein kinase, and 29-59oli-
goadenylate synthase and accounts for IFN-a-mediated anti-viral
activity [23]. To investigate whether MEK inhibitors enhanced
HCV replication by antagonizing the well-characterized anti-
viral mechanism of IFN-a, we treated HCV RLuc replicon cells
first with IFN-a/2b, followed by MEK inhibitors. Lysates were
prepared for the luciferase reporter assay. As expected, IFN-a/
2b treatment alone inhibited the luciferase reporter gene activity
(p=0.006). Treatment with IFN-a/ 2 bf o l l o w e db yM E K
inhibitors showed a significantly higher luciferase activity
compared to IFN-a treatment control alone (p=0.007), but it
was significantly lower than the MEK inhibitors alone (p=0.010)
(Fig. 2A). We also determined HCV RNA replication in these
cells. We treated the cells as above, isolated total RNA, and
performed RPA to detect plus-strand HCV RNA. In agreement
with the luciferase reporter gene activity, IFN-a/2b inhibited
plus-strand HCVRNAsynthesis(l a ne3 ,Fi g .2 B)w h enc o mp ar e d
to its PBS control (lane 2, Fig. 2B); IFN-a/2b followed by each or
both MEK inhibitors increased plus-strand HCV RNA synthesis
(lane5, 6 & 7, Fig. 2B) when compared to the IFN-a/2b plus
DMSO control (lane 4, Fig. 2B). In addition, the effect of both
inhibitors on plus-strand HCV RNA synthesis was higher than
each inhibitor alone (Fig. 2B). These findings suggest that
enhanced HCV replication by MEK inhibitors is probably
independent of the IFN-a anti-viral activity.
The basal activity of MEK was sufficient for MEK
inhibitors-enhanced HCV replication
The above experiments were conducted with cells that were
cultured in the medium containing 10% FBS, which likely
activated the basal MEK/ERK signaling. Thus, we then
determined whether the basal level of the MEK/ERK activity
Figure 1. MEK inhibitors enhanced HCV protein and RNA syntheses. HCV RLuc replicon cells were grown in a 24- or 6-well plate and treated
with either DMSO or MEK inhibitors U0126 (5 mM) and PD98059 (10 mM) for 24 hr. A. Lysates were subjected to the luciferase reporter gene activity
assay and data were expressed as mean6SEM of triplicates. KI: both MEK inhibitors. Total RNA was used for the detection of plus-strand HCV RNA
using the anti-sense RNA probe (B) and minus-strand HCV RNA using the sense RNA probe (C) by RPA. b-actin RNA was detected using a b-actin
probe to ensure loading of equal amount of RNA. The levels of plus- and minus-strand HCV RNA were determined by densitometry relative to that of
the DMSO control. The data shown are representative of three independent experiments.
doi:10.1371/journal.pone.0007498.g001
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To address this issue, we cultured HCV RLuc replicon cells in the
serum-free medium for 24 hr and then treated with MEK
inhibitors. Lysates were prepared for the luciferase reporter
activity assay, and total RNA was isolated for plus-strand HCV
RNA detection by RPA. In the absence of serum in the culture
medium, MEK inhibitors also significantly increased the luciferase
reporter gene activity when compared to the DMSO control
(p=0.006) (Fig. 3A). In parallel, MEK inhibitors also increased the
plus-strand HCV RNA level (Fig. 3B). However, it is very
interesting to note that the overall luciferase activity of the cells
cultured in the 10%-FBS-containing medium was considerably
higher than that of the cells cultured in serum-free medium,
despite that the enhancement effects by these inhibitors showed
little difference between cells cultured in the presence of serum and
in the absence of serum (Fig. 3A). This can be attributed to
activation of the phosphatidylinositol 3-kinase (PI3K)/Akt path-
way, which is the other major signaling pathway involved in
serum-dependent cell survival and growth. Taken together, these
results suggest that prior activation of MEK/ERK signaling is not
necessary for MEK inhibitors-enhanced HCV replication, but it is
involved in regulation of HCV replication.
Figure 2. MEK inhibitors-enhanceed HCV replication was independent of the IFN-a anti-viral activity. HCV replicon cells were grown in a
24- or 6-well plate in the presence of IFN-a/2b (200 IU/ml) for 24 hr and then treated with either MEK inhibitors or DMSO for 24 hr. A. Lysates were
subjected to the luciferase reporter gene assay and the data were expressed as mean6SEM of triplicates. B. Total RNA was assayed for plus-strand
HCV RNA by RPA and the data were quantitated by densitometry as above.
doi:10.1371/journal.pone.0007498.g002
Figure 3. The basal activity of MEK/ERK signaling was sufficient for MEK inhibitors-enhanced HCV replication. HCV replicon cells were
cultured in a 24- or 6-well plate in the absence or presence of serum for 24 hr and treated with either MEK inhibitors or DMSO for 24 hr. A. Lysates
were subjected to the luciferase reporter gene activity assay and the data were expressed as mean6SEM of triplicates. B. Total RNA was assayed for
plus-strand HCV RNA by RPA and the data were quantitated as above and is representative of three independent experiments.
doi:10.1371/journal.pone.0007498.g003
MEK/ERK and HCV Replication
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enhanced HCV replication
To ensure that MEK inhibitors-enhanced HCV replication was
not due to a non-specific off-target effect of these drugs and to test
whether the responsible effectors were downstream of MEK, we
took advantage of the dominant negative strategy to inactivate the
constitutive MEK-1, ERK-1, and ERK-2 activity and determined
their effects on HCV replication. HCV RLuc replicon cells were
transfected with dominant negative MEK-1, ERK-1, ERK-2
constructs [17] or an empty vector control. Lysates were prepared
at 48 hr post-transfection and the luciferase gene activity was
measured. Expression of these dominant negatives was detected by
Western blot analysis (bottom panels, Fig. 4A&B). Expression of
dominant negative MEK-1 led to a significantly higher luciferase
reporter gene activity compared to that of the control (p=0.001)
(Fig. 4A). Similarly, expression of ERK-2 dominant negative
significantly increased the luciferase reporter gene activity
(p,0.001) (Fig. 4B). However, expression of dominant negative
ERK-1 had little effect on the luciferase gene activity compared to
the control (p=0.445) (Fig. 4B). Theses results are in agreement
with those obtained with MEK inhibitors and also support the role
of MEK-1 and ERK-2 but not ERK-1 in HCV replication.
ERK-1 knockdown had no effects on HCV replication
To ascertain that ERK-1 was not involved in HCV replication,
we used the siRNA strategy to knock down the constitutive ERK-1
expression and determined its effects on HCV replication. HCV
RLuc replicon cells were transfected with ERK-1-specific siRNA
or the control siRNA. Lysates were prepared for ERK-1
expression by Western blot analysis and the effect of ERK-1
silencing on HCV was assessed by measuring the luciferase gene
activity. ERK-1 siRNA effectively knocked down the constitutive
ERK-1 expression (Fig. 5A). However, ERK-1 knockdown did not
exhibit a significant difference in the luciferase gene activity
compared to the control siRNA (p=0.45) (Fig. 5B). Both control
and ERK-1 siRNA appeared to have non-specific effects on the
level of plus-strand HCV RNA synthesis, but there was no
difference between these two transfections (Fig. 5C). Therefore,
these results further support the notion that ERK-1 does not play
any significant roles in HCV replication.
MEK inhibitors enhanced HCV replication and production
in a full-length HCV genomic system
Having found that MEK inhibitors increased HCV replication
in the subgenomic replicon cells harboringHCV genotype 1b, we
then wished to determine whether these inhibitors also increased
HCV gene expression, replication and production in other
genotypes. We addressed these questions using the recently
characterized infectious genotype 2a HCV strain JFH-1 [16]. We
transfected Huh 7.5 cells with in vitro transcribed full-length JFH-
1 RNA and then treated the cells with MEK inhibitors or the
control DMSO. Western blot analysis of cell lysates showed that
treatment of MEK inhibitors resulted in higher HCV core
p r o t e i ne x p r e s s i o nc o m p a r e dt o the DMSO control (Fig. 6A).
Analysis of total cellular RNA by real-time RT-PCR showed that
treatment of MEK inhibitors also led to a significantly higher
level of plus-strand HCV RNA compared to the DMSO control
(p=0.009) (Fig. 6B). We next determined whether the intracel-
lular increase in HCV proteins and RNA led to more
extracellular virus production. To do this, we collected
supernatants from JFH-1 RNA-transfected Huh7.5 cells that
were treated with MEK inhibitors or DMSO control, isolated the
RNA from the supernatants and quantified HCV RNA in the
supernatants by real-time RT-PCR. In agreement with the
intracellular increases in HCV protein and RNA syntheses,
treatment of MEK inhibitors led to a significantly higher level of
extracellular HCV production compared to the DMSO control
(p=0.009) (Fig. 6C). Taken together, these results indicate that
inhibition of MEK signaling increases HCV gene expression and
production in a full-length HCV genomic system, therefore
pointing to a general mechanism by which the MEK/ERK
signaling controls HCV replication.
Figure 4. Dominant negatives MEK-1 and ERK-2 but not ERK-1 up-regulated HCV replication. HCV RLuc replicon cells were transfected
with dominant negative MEK-1 (A), ERK-1 or ERK-2 (B), or the empty vector. At 48 hr post-transfection, lysates were subjected to Western blot
analysis or the luciferase reporter gene activity assay. The luciferase activity was normalized to the same number of cells. The data were expressed as
mean6SEM of triplicates.
doi:10.1371/journal.pone.0007498.g004
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cap-dependent translation
Besides regulating targets gene expression by phosphorylating
downstream transcription factors, the MEK/ERK signaling
cascade is also involved in the translational control of gene
expression through direct phosphorylation of translation factors
[5]. Thus, we also determined whether the MEK signaling was
involved in regulation of HCV IRES-dependent translation. To
test this hypothesis, we constructed a bicistronic reporter plasmid
in which HCV IRES drives the translation of the Firefly luciferase
gene while the Renilla luciferase gene is translated by a cap-
dependent mechanism (Fig. 7A). We transfected Huh 7 cells with
the bicistronic reporter, treated the cells with MEK inhibitors, and
harvested cells for the Renilla luciferase (RLuc) and Firefly luciferase
(FLuc) activity. Treatment of MEK inhibitors significantly
increased Firefly luciferase reporter gene activity, i.e. the HCV
IRES-dependent translation compared to the DMSO control
(p=0.028) (Fig. 7B). However, no statistically significant difference
for the Renilla luciferase reporter gene activity, i.e. the cap-
dependent translation was observed between cells treated with
MEK inhibitors and DMSO (p=0.56) (Fig. 7C). These results
indicate that the MEK signaling is also involved in regulation of
the HCV IRES translational activity.
Discussion
In this study, we took advantage of MEK inhibitors and
dominant negatives and demonstrated the involvement of MEK-1
and ERK-2 but not ERK-1 in HCV replication in both HCV
subgenomic and genomic systems. We found that blockage of
MEK/ERK signaling by MEK inhibitors increased HCV gene
Figure 6. MEK inhibitors enhanced HCV gene expression and virus production. Huh 7.5 cells were transfected with full-length JFH-1 RNA
and treated with either DMSO or MEK inhibitors for 48 hr. A. Lysates were analyzed for HCV core by Western blot using anti-core mAb and the blot
was re-probed for b-actin for equal protein loading. B. Total RNA was extracted and intracellular HCV RNA was quantitated by real-time RT-PCR using
the TaqMan technology. C. Supernatants were collected, concentrated, and viral RNA was isolated with Qiagen viral RNA kit. HCV RNA in the
supernatants was quantitated as above. Serially diluted in vitro transcribed HCV RNAs were used as standards for real-time RT-PCR quantitation. The
data were expressed as mean6SEM of triplicates and were representative of three independent experiments.
doi:10.1371/journal.pone.0007498.g006
Figure 5. ERK-1 knockdown had no effects on HCV replication. A. HCV replicon cells were transfected with siERK-1 (50 nM and 300 nM) or
unrelated control siRNA. Forty-eight hours post-transfection, lysates were subjected to Western blot analysis using anti-ERK-1 mAb. Blot was re-
probed with anti-b-actin mAb to ensure equal protein loading. HCV replicon cells were grown in a 24- or 6-well plate and transfected with siRNAs as
above. B. Lysates were used for the luciferase reporter gene activity assay. The data were expressed as mean6SEM of triplicates. C. Total RNA was
used for the detection of plus-strand HCV RNA by RPA using a anti-sense HCV probe. b-Actin RNA was detected as internal equal RNA loading control
using a b-actin-specific probe. RNA bands were quantified by densitometry, normalized to the b-actin internal control, and expressed as fold
induction relative to the DMSO control.
doi:10.1371/journal.pone.0007498.g005
MEK/ERK and HCV Replication
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previous studies [13,15,24]. In this study, we further looked at the
effects of these inhibitors on HCV minus-strand RNA synthesis
and found only a slight increase. This finding could be well
explained by the well-known asymmetric nature of plus- and
minus-strands HCV RNA synthesis in HCV-infected cells. HCV
RNA replication starts with the synthesis of genome-length
negative strand RNA which in turn serves as template for multiple
rounds of nascent, positive-strand RNA synthesis, leading to an
asymmetric accumulation of nearly 10 plus-strand RNA for every
single minus-strand RNA [25]. These results imply that the MEK/
ERK signaling pathway plays an important role in HCV
replication. We further examined and ruled out the possibility
that these inhibitors act off-target to produce the observed effects
by the findings that dominant negative MEK-1 expression
significantly enhanced HCV replication.
Previous studies have shown that disruption of ERK-
dependent type I IFN induction breaks the myxoma virus species
barrier [26]. Another study has also reported a negative
regulation of IFN-a-induced anti-viral response to vesicular
stomatitis virus and the Raf/MEK signaling pathway [27]. This
led us to investigate whether antagonizing the IFN-a anti-viral
activity was an alternative mechanism by which the MEK/ERK
inhibitors produce the observed effects. However, we found no
inverse correlation between the IFN-a anti-viral activity and
MEK inhibitors-enhanced HCV replication, arguing against the
possibility that these inhibitors or dominant negatives enhanced
HCV replication by interfering with the IFN-a anti-viral
response.
The MEK/ERK signaling pathway may regulate HCV
replication through direct or indirect phosphorylation of viral
and/or cellular proteins. In the case of viral proteins, for example,
phosphorylation of NS5A and NS5B proteins has been shown to
regulate HCV replication [28,29]. Moreover, selective inhibition
of cellular kinases has found an inverse correlation between NS5A
phosphorylation level and HCV RNA replication [29]. In
addition, NS5A protein is phosphophorylated on serine and
threonine residues [30,31] making it a potential substrate for MEK
kinase. While one study has shown little change in the level of
NS5A phosphorylation after treatment with the MEK kinase
inhibitor PD98059 [24], the other one has demonstrated an
inverse correlation between inhibition of MEK kinase, the level of
NS5A phosphorylation and HCV replication [15]. However, our
findings that dominant negative ERK-2 expression enhanced
HCV replication clearly suggest that the effectors of MEK kinase-
mediated control of HCV replication are located downstream of
MEK kinase. Therefore, future investigation of the direct
phosphorylation of NS5A by MEK would help determine whether
the viral NS5A is a direct substrate for this cellular kinase.
The MEK/ERK signaling pathway is involved in cell growth
and proliferation and has been a major target for anti-cancer drugs
development. HCV induces hepatocellular carcinoma in infected
individuals; our findings in this study as well as others [13,15,24]
that inhibition of MEK signaling leads to the up-regulation of
HCV replication raise concerns about the potential use of those
inhibitors for the treatment of cancer in HCV-infected individuals.
This led us to evaluate the outcome of MEK inhibitors-enhanced
HCV replication on virus production using the recently described
Figure 7. MEK inhibitors enhanced HCV IRES-dependent but not cap-dependent translation. Huh 7 cells were transfected with the
bicistronic reporter construct pC3.RLuc.HCV.IRES.Fluc (A) and treated with either DMSO or MEK inhibitors for 24 hr. Lysates were assayed for the
Firefly luciferase reporter gene activity to measure HCV IRES-dependent translational activity (B) and the Renilla luciferase reporter gene activity to
measure cap-dependent translation (C). The data were expressed as means6SEM of triplicates and were representative of three independent
experiments.
doi:10.1371/journal.pone.0007498.g007
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correlation among the increase in HCV proteins, plus-strand RNA
accumulation in the cells, and HCV production in the culture
supernatant. These findings support the notion that targeting
MEK/ERK signaling as therapeutic intervention to treat
hepatocellular carcinoma may lead to acceleration of HCV
pathogenic process. This possibility is further supported by an
early report that treatment of cells with MEK kinase inhibitor
PD98059 indeed increases the infectivity of HCV-positive serum
[24].
The MEK/ERK signaling pathway regulates target gene
expression at both the transcriptional and translational levels by
direct phosphorylation of translation factors [5]. Using a
bicistronic reporter system, we found that MEK inhibitors
enhanced HCV IRES translational activity but had no effects on
the cap-dependent translation. These findings are consistent with a
previous report [24] and supports the notion that the MEK/ERK
signaling functions to control HCV replication through the HCV
translational machinery. Furthermore, these findings suggest that
the HCV IRES translational machinery can be specifically
targeted with pharmacological agents without affecting the host
translational system.
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